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Objective: Type-2 diabetes is a progressive disease. However, little is known about whether decreased
fasting or postprandial pancreatic b-cell responsiveness is more prominent with increased duration of
diabetes. The aim of this study was to evaluate the relationship between insulin secretion both during
fasting and 2 h postprandial, and the duration of diabetes in type-2 diabetic patients.
Design: Cross-sectional clinical investigation.
Methods: We conducted a meal tolerance test in 1466 type-2 diabetic patients and calculated fasting
(M0) and postprandial (M1) b-cell responsiveness.
Results: The fasting C-peptide, postprandial C-peptide,M0, andM1 values were lower, but HbA1c values
were higher, in patients with diabetes durationO 10 years than those in other groups. There was no
difference in the HbA1c levels according to the tertiles of their fasting C-peptide level. However, in a
group of patients with highest postprandial C-peptide tertile, the HbA1c values were significantly lower
than those in other groups. After adjustment of age, sex, and body mass index (BMI), the duration of
diabetes was found to be negatively correlated with fasting C-peptide (gZK0.102), postprandial C-
peptide (gZK0.356), M0 (gZK0.263), and M1 (gZK0.315; P!0.01 respectively). After
adjustment of age, sex, and BMI, HbA1c was found to be negatively correlated with postprandial C-
peptide (gZK0.264), M0 (gZK0.379), and M1 (gZK0.522), however, positively correlated with
fasting C-peptide (gZ0.105; P!0.01 respectively). In stepwise multiple regression analysis, M0, M1,
and homeostasis model assessment for insulin resistance (HOMA-IR) emerged as predictors of HbAlc
after adjustment for age, sex, and BMI (R2Z0.272, 0.080, and 0.056 respectively).
Conclusions: With increasing duration of diabetes, the decrease of postprandial insulin secretion is
becoming more prominent, and postprandial b-cell responsiveness may be a more important
determinant for glycemic control than fasting b-cell responsiveness.
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A variety of oral glucose and meal tolerance tests have
extensively been used to diagnose type-2 diabetes
mellitus in a clinical setting. The oral load results in a
typical postprandial exposure of the pancreas to glucose,
nutrient (protein and fat), and gut and vagal hormones.
The measurement of pancreatic responsiveness, there-
fore, closely reflects the ability of the pancreas to produce
insulin under normal physiological conditions (1).
The results of United Kingdom Prospective Diabetes
Study indicate that, in the group with intensive
treatment, it took 6 and 4 years before the fasting
plasma glucose level and HbA1c returned to the
pretherapy level respectively, and the difference may
reflect increasing postprandial hyperglycemia (2).
Relative contribution of fasting and postprandial plasman Journal of Endocrinologyglucose to the HbA1c remains to be uncertain; some
researchers support fasting plasma glucose values to be a
better predictor for the overall glycemia as reflected by
the HbA1c value (3), whereas others favor postprandial
plasma glucose as a better predictor (4–6). Results from
studies aimed at reducing postprandial glycemia support
the latter claim (7, 8). Therefore, postprandial glucose
concentration appears to contribute more or at least
equally to the overall glycemia than fasting glucose
concentration. Furthermore, decreased postprandial
insulin response most plausibly explains elevated fasting
plasma glucose, HbA1c, and glucose responses to meal in
newly presenting type-2 diabetic patients (9).
Todate, most studies on the b-cell function in type-2
diabetes had some limitations: (i) only fasting insulin
secretion was measured (2), or (ii) postprandial insulin
secretion was measured in a small number of patientsDOI: 10.1530/eje.1.02249
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fasting and postprandial 2-h insulin secretion with the
duration of diabetes and glycemic control in a large
number of type-2 diabetic patients, whose durations of
diabetes are varied. Therefore, we undertook to
examine the relationship of insulin secretion during
fasting and postprandial 2 h with the duration of
diabetes and glycemic control in Korean type-2 diabetic
patients.Subjects and methods
Study subjects
Randomly selected type-2 diabetic patients (nZ1466,
810 males and 656 females), who visited the Diabetes
Center at Severance Hospital, Yonsei University Medical
Center from June 2002 to April 2005 for glycemic
control were enrolled in this study. Their treatment
methods were not changed during the last 3 months.
Patients presenting with symptoms suggestive of type-1
diabetes, defined as diabetic ketoacidosis, acute
presentation with heavy ketonuria (3C), or continu-
ous requirement of insulin within 1 year of diagnosis
were excluded. Patients with glutamic acid decarboxy-
lase antibody positivity were excluded. Patients who
had taken steroid or renal impairment (plasma Cr
higher than 1.5 mg/dl) were also excluded. Further-
more, 54 patients with insulin treatment were also
included. The insulin concentration data on patients
with insulin treatment were excluded from the analysis.
The Ethics Committee of Yonsei University College of
Medicine, Seoul, approved this study, and informed
consent was obtained from each subject.Methods
Subjects’ height and weight were measured to the
nearest 0.1 cm and 0.1 kg respectively. They were
allowed to wear light clothing but not to wear shoes.
Body mass index (BMI) was calculated as weight (kg)
over the square of the height (m2). Blood samples were
collected after 12-h fasting. Fasting glucose was
measured by the glucose oxidase method. HbA1c was
analyzed by HPLC (Variant II; Bio-Rad; coefficient of
variation (CV)Z2.1%). Insulin concentration was
measured by IRMA (RIABEAD II kit, Abbott, Japan;
intra-assay CV 1.2–1.9%, inter-assay CV 1.4–3.3%).
The concentration of C-peptide was measured by RIA
(DiaSorin, Stillwater, MN, USA; CVZ2.7%).
After obtaining fasting blood samples, patients were
allowed to eat one type of meal selected from a few
standardized meals (total 823G132 kcal containing,
protein 17.7G4.6%, fat 16.3G6.4%, and carbohydrate
65.9G10.0%), while medications were taken as usual.
The concentration of serum glucose, insulin, and
C-peptide was measured 2 h after the meal. Currentlywww.eje-online.orgused oral hypoglycemic agents were examined: one
tablet of sulfonylureawas considered as 80 mg gliclazide
or 2 mgglimepiride (10), and one tablet of biguanidewas
considered as 500 mg metformin. With regard to
a-glucosidase inhibitor, 0.2 mg voglibose were
considered to be equivalent to 100 mg acarbose (11).
Rosiglitazone (4 mg) and pioglitazone (15 mg) were
considered to be equivalent (12, 13).
D Insulin concentration was defined as the post-
prandial 2-h insulin concentration minus fasting
insulin concentration, and D C-peptide concentration
as the postprandial 2-h C-peptide concentration minus
fasting C-peptide concentration.
Fasting b-cell responsiveness (M0) represents the
ability of fasting glucose to stimulate b-cell secretion
(1) and postprandial b-cell responsiveness (M1)
represents the ability of postprandial glucose to step
up b-cell secretion (1), and they were calculated using
the formula of Hovorka et al. (1) with some modifi-
cation:
M0Z100! fasting C  peptide ðmg=lÞ=fasting glucose
concentration ðmg=dlÞ
M1Z100 ðpostprandial 2-h CKpeptide concentration ðmg=lÞ
Kfasting CKpeptide concentration ðmg=lÞÞ=ðpostprandial
2-h glucose concentration ðmg=dlÞKfasting glucose
concentration ðmg=dlÞÞ
As an indicator of insulin resistance, this study used
the homeostasis model assessment for insulin resistance
(HOMA-IR), which was calculated as follows (14):
HOMA-IRZ ðfasting insulin ðmU=mlÞ
!fasting glucose ðmmol=lÞ=22:5Þ
According to the duration of diabetes, the subjects
were divided into three groups; shorter than 5 years,
from 5 years to less than 10 years, and longer than 10
years for analysis. According to their fasting, post-
prandial and D C-peptide concentrations, the subjects
were divided into three groups. After adjustment for
age, sex, and BMI, the correlation between duration of
diabetes, HbA1c, and other metabolic parameters was
analyzed.Statistical analysis
Statistical analyses were performed using SPSS soft-
ware (version 13.0; SPSS, Inc., Chicago, IL, USA). All
continuous variables are expressed as meanGS.D.,
except insulin, C-peptide, HOMA-IR, M0, and M1,
which are described as median and range and were
log-transformed to accommodate skewing of the
distribution. Comparisons between groups classified
by the duration of diabetes, fasting C-peptide, post-
prandial C-peptide, and D C-peptide value were
performed by using ANOVA followed by post hoc testing
Fasting versus postprandial insulin secretion 617EUROPEAN JOURNAL OF ENDOCRINOLOGY (2006) 155with Tukey’s test. The c2 test was used for categorical
variables. Partial Pearson’s correlation coefficiency
between the duration of diabetes and HbA1c, and
other metabolic parameters were preformed after
adjustment of age, sex, and BMI. Stepwise multiple
regression analysis with HbA1c as a dependent variable
was performed. Variables of age, gender, BMI, M0, M1,
and HOMA-IR were analyzed as independent variables.
A two-sided value of P!0.05 was considered to be
statistically significant.Results
Clinical characteristics of patients
The mean age of patients was 55.0G11.5 years, the
mean duration of diabetes was 5.0G5.7 years, mean
BMI was 25.4G3.2 kg/m2, and the median concen-
trations of fasting, postprandial, and D C-peptide were
1.54 (0.54–6.70) mg/l, 3.74 (1.01–17.63) mg/l, and
2.11 (0.01–14.84) mg/l respectively.Clinical characteristics according to the
duration of diabetes
In the group with diabetes for longer than 10 years,
their age, and HbA1c value were higher, and their BMI,
fasting C-peptide, postprandial C-peptide, fasting insu-
lin, postprandial insulin, D insulin, D C-peptide, fastingTable 1 Clinical characteristics according to the duration of diabetes.
values are described as median (range) values.
Duration of diabetes (years) !5
n 887
Age (years) 52.3G11.9
Sex (female %) 42
BMI (kg/m2) 25.7G3.3
Fasting glucose (mmol/l) 7.50G2.09
PP 2-h glucose (mmol/l) 11.54G4.24
HbA1c (%) 7.5G1.6
Fasting insulin (pmol/l) 51.1 (4.8–234.8)
PP 2-h insulin (pmol/l) 267.1 (17.7–2152.5)
Fasting C-peptide (mg/l) 1.60 (0.69–5.70)
PP 2-h C-peptide (mg/l) 4.21 (1.03–17.63)
D Insulin (pmol/l) 210.9 (2.7–1972.2)
D C-peptide (mg/l) 2.50 (0.02–14.84)
M0 1.25 (0.35–6.79)
M1 3.30 (K481.0–372.0)
HOMA-IR 2.27 (0.31–16.54)
No. of tablet of sulfonylurea 0.18G0.39
No. of tablet of metformin 0.70G1.01
No. of tablet of AGL 0.09G0.43
No. of tablet of TZD 0.05G0.19
No. of tablet of other OHA 0.04G0.29
Prevalence of insulin user (%) 0.2
BMI, body mass index; PP, postprandial; M0, fasting b-cell responsiveness; M1
thiolidinedione; OHA, oral hypoglycemic agents; HOMA-IR, homeostatic model a
hoc and Tukey’s test). *P!0.05 between groups (duration of diabetes below 5 ye
between groups (duration of diabetes below 5 years versus duration of diabete
years and below 10 years versus duration of diabetes above 10 years).b-cell responsiveness, and postprandial b-cell respon-
siveness were lower than those in other groups. The
number of tablets of sulfonylurea, metformin,
a-glucosidase inhibitor, and thiazolidinedione used
were higher than those in the group with diabetes for
less than 5 years. Furthermore, the prevalence of
patients with insulin treatment was higher (Table 1).Clinical characteristics according to the ter-
tiles of fasting C-peptide level
In the group with highest fasting C-peptide tertile, their
duration of diabetes was shortest. Their BMI, fasting
insulin, postprandial insulin, postprandial C-peptide,
D insulin, D C-peptide, fasting b-cell responsiveness, and
postprandial b-cell responsiveness were higher than
those of other groups. However, the concentrations of
fasting glucose, postprandial glucose, and HbA1c were
not different among the three groups (Table 2).Clinical characteristics according to the
tertiles of postprandial C-peptide level
In the group with highest postprandial C-peptide tertile,
their duration of diabetes was shorter, and their BMI,
fasting insulin, postprandial insulin, fasting C-peptide,
D insulin, D C-peptide, fasting b-cell responsiveness, and
postprandial b-cell responsiveness were higher than
those of the other two groups. However, theData are expressed as meanGS.D. Insulin, C-peptide, M0, and M1
R5–!10 R10
240 339
55.8G10.1* 59.9G9.6†‡
48 48
25.3G2.9 24.5G3.0†‡
8.63G2.38* 8.93G2.59†
13.76G4.18* 14.32G4.53†
8.0G1.5* 8.4G1.5†‡
50.3 (10.0–212.5) 42.5 (8.4–225.7)†‡
194.2 (26.3–1123.1)* 150.2 (20.0–900.2)†‡
1.56 (0.70–6.70) 1.39 (0.54–3.72)†‡
3.43 (1.27–14.69)* 2.90 (1.01–8.50)†‡
144.4 (7.3–984.5)* 103.5 (0.5–760.4)†‡
1.88 (0.05–7.99)* 1.49 (0.01–7.22)†‡
1.02 (0.42–3.99)* 0.91 (0.27–3.14)†‡
1.88 (K252.0–67.7)* 1.42 (K81.0–53.3)†‡
2.42 (0.33–16.66) 2.17 (0.40–12.06)
0.83G0.68* 1.16G0.87†‡
1.46G1.21* 1.37G1.21†
0.47G1.16* 0.57G1.10†
0.16G0.37* 0.16G0.35†
0.02G0.27 0.08G0.45
2.5 13.6†‡
, postprandial b-cell responsiveness; AGL, a-glucose inhibitor; TZD,
ssessment of insulin resistance. P value was obtained from the ANOVA (post
ars versus duration of diabetes above 5 years and below 10 years). †P!0.05
s above 10 years). ‡P!0.05 between groups (duration of diabetes above 5
www.eje-online.org
Table 2 Clinical characteristics according to the tertile of fasting C-peptide level. Data are expressed as meanGS.D. Insulin, C-peptide, M0,
and M1 values are described as median (range) values.
Tertile of fasting C-peptide Tertile 1 Tertile 2 Tertile 3
n 489 493 484
C-peptide range (mg/l) 0.54–1.33 1.34–1.83 1.84–6.70
Age (years) 56.0G10.7 55.1G11.5 54.0G12.1†
Sex (female %) 50 42* 43
Duration of diabetes (years) 6.3G6.5 5.0G5.6* 3.7G4.6†‡
BMI (kg/m2) 24.1G2.8 25.3G2.9* 26.7G3.3†‡
Fasting glucose (mmol/l) 7.85G2.51 8.12G2.30 8.08G2.21
PP 2-h glucose (mmol/l) 12.38G4.71 12.56G4.40 12.66G4.31
HbA1c (%) 7.7G1.6 7.8G1.6 7.9G1.5
Fasting insulin (pmol/l) 28.6 (4.8–219.0) 46.2 (8.8–153.5)* 74.4 (10.9–234.8)†‡
PP 2-h insulin (pmol/l) 158.4 (17.7–1123.1) 211.6 (25.8–1486.1)* 326.4 (25.6–2152.5)†‡
PP 2-h C-peptide (mg/l) 2.86 (1.01–10.70) 3.57 (1.39–9.54)* 5.19 (2.07–17.63)†‡
D Insulin (pmol/l) 120.5 (0.9–984.5) 160.5 (0.5–1411.9)* 251.1 (0.9–1972.2)†‡
D C-peptide (mg/l) 1.79 (0.01–9.70) 2.03 (0.05–7.81)* 2.73 (0.02–14.84)†‡
M0 0.80 (0.27–1.74) 1.14 (0.56–2.53)* 1.71 (0.75–6.79)
†‡
M1 1.94 (K252.0–176.5) 2.24 (K161.5–372.0) 3.11 (K481.0–332.0)
†‡
HOMA-IR 1.36 (0.31–9.11) 2.24 (0.31–10.77)* 3.64 (0.35–16.66)†‡
No. of tablet of sulfonylurea 0.47G0.63 0.49G0.65 0.44G0.64
No. of tablet of metformin 1.02G1.13 1.03G1.13 0.87G1.15
No. of tablet of AGL 0.27G0.76 0.25G0.73 0.24G0.74
No. of tablet of TZD 0.15G0.31 0.07G0.22* 0.07G0.23*
No. of tablet of other OHA 0.04G0.30 0.04G0.29 0.05G0.36
Prevalence of insulin user (%) 6.7 2.8* 1.4*
BMI, body mass index; PP, postprandial; M0, fasting b-cell responsiveness; M1, postprandial b-cell responsiveness; HOMA-IR, homeostatic model
assessment of insulin resistance; AGL, a-glucose inhibitor; TZD, thiolidinedione; OHA, oral hypoglycemic agents. P value was obtained from the ANOVA
(post hoc and Tukey’s test). *P!0.05 between groups (tertile 1 versus tertile 2). †P!0.05 between groups (tertile 1 versus tertile 3). ‡P!0.05 between groups
(tertile 2 versus tertile 3).
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than those of other groups, although they used the
lowest dosage of sulfonylurea and metformin among the
three groups. The prevalence of patients with insulin
treatment was lower (Table 3).Clinical characteristics according to the
tertiles of D C-peptide level
In the group with highest D C-peptide tertile, subjects’
duration of diabetes was shorter, and their BMI, fasting
insulin, postprandial insulin, fasting C-peptide, post-
prandial C-peptide, D insulin, fasting b-cell responsive-
ness, and postprandial b-cell responsiveness were
higher than those of the other two groups. However,
the concentrations of fasting glucose, postprandial
glucose, and HbA1c were lower than those of the
other groups, although they used the lowest dosage of
sulfonylurea and metformin among the three groups.
The prevalence of patients with insulin treatment was
lower (Table 4).The distribution of C-peptide according to the
duration of diabetes
The distribution of fasting C-peptide, postprandial
C-peptide, and D C-peptide concentrations according
to the duration of diabetes were shown in Fig. 1A–C
respectively.www.eje-online.orgRelationship between the duration of diabetes
and other metabolic parameters
After adjustment of age, sex, and BMI, the duration of
diabetes was found to be negatively correlated with
fasting insulin (gZK0.098), postprandial insulin
(gZK0.315), fasting C-peptide (gZK0.102), post-
prandial C-peptide (gZK0.356), D insulin
(gZK0.309), D C-peptide (gZK0.358), fasting
b-cell responsiveness (gZK0.263), and postprandial
b-cell responsiveness (gZK0.315), but positively with
fasting glucose (gZ0.272), postprandial glucose (gZ
0.241), and HbA1c (gZ0.210) (P!0.001, except for
fasting insulin P!0.01).Relationship between HbA1c and other
metabolic parameters
After adjustment of age, sex, and BMI, HbA1c was found
to be positively correlated with the duration of diabetes
(gZ0.210), fasting glucose (gZ0.704), postprandial
glucose (gZ0.685), and fasting C-peptide (gZ0.105),
but negatively with postprandial insulin (gZK0.294),
postprandial C-peptide (gZK0.264), d insulin (gZK
0.306), D C-peptide (gZK0.352), fasting b-cell
responsiveness (gZK0.379), and postprandial b-cell
responsiveness (gZK0.522; P!0.001). However,
correlation with fasting insulin concentration was not
significant.
Table 3 Clinical characteristics according to the tertile of postprandial 2-h C-peptide level. Data are expressed as meanGS.D. Insulin,
C-peptide, M0, and M1 values are described as median (range) values.
Tertiles of PP 2-h C-peptide Tertile 1 Tertile 2 Tertile 3
n 481 493 492
C-peptide range (mg/l) 1.01–3.11 3.12–4.45 4.46–17.63
Age (years) 55.2G11.0 55.1G11.0 54.8G12.3
Sex (female %) 47 44 43
Duration of diabetes (years) 7.5G6.5 4.8G5.4* 2.8G4.0†‡
BMI (kg/m2) 24.3G3.0 25.5G3.1* 26.3G3.2†‡
Fasting glucose (mmol/l) 8.84G2.76 7.95G2.09* 7.28G1.84†‡
PP 2-h glucose (mmol/l) 13.28G4.95 12.51G4.42* 11.87G3.92†
HbA1c (%) 8.3G1.8 7.7G1.5* 7.4G1.4
†‡
Fasting insulin (pmol/l) 34.3 (4.8–153.5) 46.9 (9.9–219.0)* 62.7 (11.3–234.8)†‡
PP 2-h insulin (pmol/l) 114.6 (17.7–528.3) 225.6 (42.8–790.0)* 408.4 (46.0–2152.5)†‡
Fasting C-peptide (mg/l) 1.22 (0.54–2.91) 1.53 (0.70–3.91)* 2.10 (0.82–6.70)†‡
D Insulin (pmol/l) 76.1 (0.5–448.2) 177.8 (4.6–619.2)* 341.6 (3.6–1972.2)†‡
D C-peptide (mg/l) 1.09 (0.01–2.27) 2.14 (0.02–3.51)* 3.69 (0.70–14.84)†‡
M0 0.81 (0.27–2.84) 1.12 (0.43–3.12)* 1.59 (0.48–6.79)
†‡
M1 1.09 (K88.0 to 63.5) 2.25 (K252.0–167.0)* 4.56 (K481.0–372.0)
†‡
HOMA-IR 1.76 (0.31–10.77) 2.25 (0.38–16.54)* 2.75 (0.49–16.66)†‡
No. of tablet of sulfonylurea 0.64G0.74 0.51G0.66 0.29G0.49†‡
No. of tablet of metformin 1.21G1.26 1.03G1.13 0.68G1.00†‡
No. of tablet of AGL 0.33G0.84 0.27G0.78 0.16G0.60
No. of tablet of TZD 0.11G0.28 0.10G0.26 0.07G0.23
No. of tablet of other OHA 0.03G0.25 0.04G0.30 0.06G0.38
Prevalence of insulin user (%) 8.7 1.8* 0.6†
BMI, body mass index; PP, postprandial; M0, fasting b-cell responsiveness; M1, postprandial b-cell responsiveness; HOMA-IR, homeostatic model
assessment of insulin resistance; AGL, a-glucose inhibitor; TZD, thiolidinedione; OHA, oral hypoglycemic agents. P value was obtained from the ANOVA (post
hoc and Tukey’s test). *P!0.05 between groups (tertile 1 versus tertile 2). †P!0.05 between groups (tertile 1 versus tertile 3). ‡P!0.05 between groups (tertile
2 versus tertile 3).
Table 4 Clinical characteristics according to the tertile of D C-peptide level. Data are expressed as meanGS.D. Insulin, C-peptide, M0, and
M1 values are described as median (range) values.
Tertiles of D C-peptide Tertile 1 Tertile 2 Tertile 3
n 488 491 487
C-peptide range (mg/l) 0.01–1.59 1.60–2.70 2.71–14.84
Age (years) 54.4G11.2 55.5G11.3 54.8G12.3
Sex (female %) 47 44 43
Duration of diabetes (years) 7.3G6.4 5.1G5.6* 2.8G4.0†‡
BMI (kg/m2) 24.7G3.2 25.3G3.0* 26.3G3.2†‡
Fasting glucose (mmol/l) 9.04G2.65 7.97G2.16* 7.28G1.84†‡
PP 2-h glucose (mmol/l) 13.54G4.87 12.56G4.58* 11.87G3.92†‡
HbA1c (%) 8.5G1.7 7.7G1.5* 7.4G1.4
†‡
Fasting insulin (pmol/l) 42.1 (4.8–192.4) 45.0 (10.0–234.8)* 55.2 (9.9–228.3)†‡
PP 2-h insulin (pmol/l) 117.7 (20.0–503.5) 216.8 (17.7–907.2)* 407.5 (46.0–2152.5)†‡
Fasting C-peptide (mg/l) 1.39 (0.54–5.12) 1.51 (0.70–5.70)* 1.84 (0.76–6.70)†‡
PP 2-h C-peptide (mg/l) 2.48 (1.01–5.82) 3.65 (2.50–8.05)* 5.58 (3.53–17.63)†‡
D insulin (pmol/l) 74.3 (0.5–398.5) 168.0 (2.7–795.9)* 344.0 (3.6–1972.2)†‡
M0 0.90 (0.27–3.21) 3.65 (2.50–8.05)* 1.45 (0.48–4.42)
†‡
M1 1.00 (K88.0–63.5) 2.18 (0.3–16.7)* 4.77 (K481.0–372.0)
†‡
HOMA-IR 2.29 (0.31–16.54) 2.18 (0.33–16.66) 2.38 (0.38–10.80)
No. of tablet of sulfonylurea 0.65G0.76 0.48G0.63* 0.27G0.47†‡
No. of tablet of metformin 1.20G1.27 1.01G1.12 0.72G0.98†‡
No. of tablet of AGL 0.36G0.89 0.23G0.74 0.15G0.57
No. of tablet of TZD 0.09G0.26 0.12G0.29 0.07G0.22
No. of tablet of other OHA 0.04G0.29 0.03G0.25 0.07G0.39
Prevalence of insulin user (%) 9 1.0* 1.0†
BMI, body mass index; PP, postprandial; M0, fasting b-cell responsiveness; M1, postprandial b-cell responsiveness; HOMA-IR, homeostatic model
assessment of insulin resistance; AGL, a-glucose inhibitor; TZD, thiolidinedione; OHA, oral hypoglycemic agents. P value was obtained from the ANOVA (post
hoc and Tukey’s test). *P!0.05 between groups (tertile 1 versus tertile 2). †P!0.05 between groups (tertile 1 versus tertile 3). ‡P!0.05 between groups (tertile
2 versus tertile 3).
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Figure 1 The distribution of C-peptide levels according to the duration of diabetes. (A) Fasting C-peptide, (B) postprandial 2-h C-peptide,
and (C) D C-peptide. D C-peptide concentration was defined as the postprandial 2-h C-peptide concentration minus fasting C-peptide
concentration. Horizontal lines indicate the median value of fasting C-peptide, postprandial 2-h C-peptide, and D C-peptide level
respectively.
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dependent variable
In stepwise multiple regression analysis, M0, M1, and
HOMA-IR emerged as predictors of HbA1c. When M1
was used as a predictor of HbA1c, R
2 was 0.272.
When M1 and HOMA-IR were used as predictors of
HbA1c, R
2 was 0.328. When M1, HOMA-IR, and M0
were used as predictors of HbA1c, R
2 was 0.408. M1
explained 27.2% of the variation in the change of
HbA1c. The addition of HOMA-IR to M1 explained an
additional 5.6% of the variation in the change of
HbA1c. The addition of M0 to M1 and HOMA-IR
explained an additional 8% of the variation in the
change of HbA1c than M1 plus HOMA-IR.Discussion
Failure of pancreatic b-cells to secrete adequate
insulin to maintain normoglycemia is a prerequisite
in the development of type-2 diabetes. Therefore, it is
important to evaluate pancreatic b-cell function,
which may be a good index of predicting glycemicwww.eje-online.orgcontrol and prognosis. The meal tolerance test is
more physiological test to measure the pancreatic
b-cell function, and it can also distinguish the diverse
range response of pancreas (1).
The present results showed that fasting C-peptide, D
C-peptide, postprandial C-peptide, fasting b-cell
responsiveness, and postprandial b-cell responsiveness
were decreased, but fasting glucose, postprandial
glucose, and HbA1c values were increased with the
increase of the duration of diabetes. These results
indicate that fasting and postprandial b-cell functions
and the degree of glycemic control have deteriorated
with the duration of diabetes in type-2 diabetic patients,
indicating type-2 diabetes is a progressive disease as
shown in the previous study (2). In type-2 diabetic
patients, b-cell function assessed by the HOMA method
deteriorated in subjects on diet therapy. In subjects on
continuing sulfonylurea therapy, b-cell function
assessed by the HOMA method increased in the first
year but subsequently decreased at 6 years (2).
Furthermore, fasting and postprandial 1-h C-peptide
levels decreased significantly with the duration of
diabetes in type-2 diabetic patients (15).
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secretion was decreased with the increase in the
duration of diabetes is in good agreement with those
studies with type-1 diabetes (16). Among 2432
patients diagnosed as type-1 diabetes after the age
of 18 years, the patients with 1–5 years duration at
the time of eligibility screening, stimulated C-peptide
was R0.2 nmol/l in 48% of the cases and O
0.5 nmol/l in 15% of the cases; whereas for those
with O5–15 years duration, stimulated C-peptide
was R0.2 nmol/l in 8% and O0.5 nmol/l in 2% of
the cases (16).
In a study for the prevention of type-1 diabetes, it was
found no fall of C-peptide (peak and area under the
curve) production over time in non-progressors,
compared with progressors, regardless of type of
tolerance testing employed (mixed meal, oral, or i.v.)
(17). These results suggest that the preservation of
C-peptide production in the prediabetic period appears
to indicate non-progression to clinical disease and may
serve as a new surrogate for determining response to
preventative efforts. Based on the earlier descriptions,
postprandial C-peptide level seems to be used as a
progression marker of diabetes not only for the group
with high risk of diabetes and type-1 diabetes, but also
for the group with type-2 diabetes.
The results of this study showed that the decrease of
postprandial C-peptide and b-cell responsiveness, which
represent postprandial b-cell function, was more
prominent than fasting C-peptide and b-cell responsive-
ness with the increase of the duration of diabetes. These
results are consistent with the results obtained with the
newly presenting type-2 diabetic patients (9). The
postprandial b-cell responsiveness was reduced by
about 80% compared with BMI-matched healthy
subjects, whereas fasting b-cell responsiveness was
reduced by approximately 50% in the newly presenting
type-2 diabetic subjects. Taken together, these results
suggest that the reduction of postprandial b-cell
responsiveness was more prominent than fasting
b-cell responsiveness not only in the early stage of
type-2 diabetes, but also in the late stage of type-2
diabetes.
In this study, HbA1c value of patients with the
highest tertile of postprandial C-peptide value was
significantly lower than in other groups although they
had taken the lowest amount of oral hypoglycemic
agents, which is consistent with the study on type-1
diabetes mellitus (18). Patients whose C-peptide levels
were increased to over 0.20 pmol/ml had better
metabolic control, and their HbA1c and fasting and
postprandial glucose values were lower although they
received less insulin. Furthermore, C-peptide values as
low as 0.10–0.20 pmol/ml may also have an impact
on diabetic management, since patients in this group
required less exogenous insulin to achieve the same
level of glycemic control, as those whose stimulated
levels were 0.05 pmol/ml or less (18). In other words,even though insulin-secretory capacity is absolutely
decreased in type-1 diabetes, peak postprandial
C-peptide concentration is important for glycemic
control.
In this study, although HbA1c was correlated with
both fasting and postprandial b-cell responsiveness, it
was more closely correlated with postprandial b-cell
responsiveness. Indeed, postprandial insulin deficiency
is the most plausible factor underlying elevated fasting
plasma glucose, HbA1c and glucose responses to meal in
newly presenting type-2 diabetic patients (9), implying
that the postprandial b-cell responsiveness is the most
important factor in glycemic control not only in the
newly presenting diabetic patients, but also in the
patients with diverse durations of diabetes.
Type-2 diabetes is characterized by defects in both
insulin secretion and insulin sensitivity (19). While
hyperglycemia can result from both insulin resistance
and b-cell dysfunction, there has been much debate
over the past few decades regarding the relative
importance of these two abnormalities in the develop-
ment of type-2 diabetes (20–23). In this study, M1 and
M0 explained 27.2 and 8.0% respectively, of the
variation in the chance of HbA1c, while HOMA-IR
explained 5.6% of variation. These results suggest
that, although insulin resistance is a crucial factor in
glycemic control, insulin secretion, especially
postprandial b-cell responsiveness, may be more
important in the regulation of glycemic control than
insulin resistance. However, since there are various
ethnic differences in insulin resistance and b-cell
function (24), more studies are required to assess
the role of insulin secretion, postprandial b-cell
responsiveness in particular, and peripheral insulin
resistance in glycemic control in various ethnic
population.
The limitation of our study is its cross-sectional
nature. Nevertheless, this constitutes the largest scaled
study on the fasting and postprandial insulin secretion,
which was examined by the meal tolerance test, in type-
2 diabetic patients, whose duration of diabetes was
varied. In summary, fasting and postprandial insulin
secretions were found to decrease as the duration of
diabetes was increased, and particularly, postprandial
insulin secretion was more prominently decreased.
Furthermore, in comparison with fasting b-cell
responsiveness, postprandial b-cell responsiveness was
observed to exert greater effect on glycemic control in
type-2 diabetes mellitus.Acknowledgements
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